Orphazyme finishes enrollment in phase 3 study assessing arizoclomol
Category: #healthcare  By Akshay Kedari  Date: 2019-07-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Orphazyme finishes enrollment in phase 3 study assessing arizoclomol

The phase 3 study of arimoclomol for ALS is a 76-week, placebo-controlled, randomized study being conducted at 30 centers of excellence in Europe and North America.

The biopharmaceutical company Orphazyme A/S has reportedly announced that it has finished enrollment in its phase 3 study assessing arimoclomol for the treatment of Amyotrophic Lateral Sclerosis (ALS) before schedule. The full analysis remain on track for the first half of 2021.

Apparently, the trial has completed enrollment earlier than expected with the support of the global ALS community and contribution of hundreds of people living with ALS and their care partners. A provisional analysis of the data is no longer required due to the proximity of the final data sets to the planned interval analysis.

Michael Benatar, MD, Lead International Coordinating Investigator, Orphazyme, reportedly stated that the company is grateful to the diligent efforts of coordinators and investigators at participating centers throughout the world which enabled it to reach the important achievement, taking it one step nearer to definitively learning of benefits of arimoclomol for patients living with ALS.

Thomas Blaettler, MD, Chief Medical Officer, Orphazyme, reportedly stated that the conclusion of enrollment for pivotal ALS trial of Orphazyme is another great achievement for its clinical development program.

Calaneet Balas, President and CEO, ALS Association, Chairwoman, International Alliance of ALS/MND Associations, reportedly noted that the company is obliged to the hundreds of individuals tolerating ALS around the world for participating in the trial. Subjects urgently need new treatments for ALS and the company looks forward to the results.

Phase 3 study of arimoclomol for ALS is a 76-week, placebo-controlled, randomized study being conducted at 30 centers of excellence in Europe and North America. A sum of 213 subjects have been randomized 2:1 to arimoclomol and placebo and up to an extra 18 subjects on stable therapy with edaravone may join the U.S. Patients completing the study will be offered participation in an open-label extension trial.

Source credit: https://www.orphazyme.com/news-feed/2019/7/18/orphazyme-completes-enrollment-in-phase-3-trial-evaluating-arimoclomol-in-amyotrophic-lateral-sclerosis

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Momotaro doses first patient with MTG201 in its Phase 2 clinical trial
Momotaro doses first patient with MTG201 in its Phase 2 clinical trial
By Akshay Kedari

The Phase 2 study will register approx. twelve patients diagnosed with malignant mesothelioma that...

Servier, Ipsen release initial Phase II/III clinical data of ONIVYDE®
Servier, Ipsen release initial Phase II/III clinical data of ONIVYDE®
By Akshay Kedari

The results from the Phase II/III trials, which involved efficacy data and preliminary safety, was p...

Ceridian inks an agreement to acquire WFM solution provider RITEQ
Ceridian inks an agreement to acquire WFM solution provider RITEQ
By Akshay Kedari

The acquisition would advance Ceridian’s momentum in New Zealand and the Australian markets. ...